MediBeacon TGFR article named 2025 JASN Editors’ Choice; commercial rollout started Jan 2026

INNOVATE Corp.

MediBeacon's transdermal GFR article selected as one of five 2025 Editors' Choice articles by JASN.
TGFR System uses Lumitrace injection and transdermal sensor to measure kidney function at point of care.
INNOVATE holds 44.7% equity interest in MediBeacon; commercialization began Jan 2026 in select academic centers.
Initial clinical focus: heart failure monitoring, transplant evaluation, and oncology drug dosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.